Treatment for C. difficile Colitis
For initial C. difficile infection, use fidaxomicin 200 mg twice daily for 10 days as first-line therapy; vancomycin 125 mg four times daily for 10 days is an acceptable alternative if fidaxomicin is unavailable or cost-prohibitive. 1
Initial Episode Treatment Algorithm
The 2021 IDSA/SHEA guidelines establish a clear hierarchy based on disease severity:
Non-Severe CDI
- Preferred: Fidaxomicin 200 mg PO twice daily × 10 days
- Alternative: Vancomycin 125 mg PO four times daily × 10 days
- Last resort (only if above unavailable): Metronidazole 500 mg PO three times daily × 10-14 days
Non-severe disease is defined by WBC ≤15,000 cells/μL AND serum creatinine <1.5 mg/dL. 1
Critical caveat: Metronidazole is no longer recommended when fidaxomicin or vancomycin are available, representing a major shift from previous guidelines. 2
Fulminant CDI
For patients presenting with hypotension, shock, ileus, or megacolon:
- Vancomycin 500 mg PO or NG four times daily (note the higher dose)
- PLUS intravenous metronidazole 500 mg every 8 hours (particularly critical if ileus present)
- If ileus: Add rectal vancomycin instillation (500 mg in 100-500 mL saline every 6 hours as retention enema)
- Early surgical consultation is mandatory 1
Recurrent CDI Management
First Recurrence
Preferred: Fidaxomicin 200 mg twice daily × 10 days, OR extended regimen (twice daily × 5 days, then every other day × 20 days)
Alternatives:
- Tapered/pulsed vancomycin: 125 mg four times daily × 10-14 days, then twice daily × 7 days, then once daily × 7 days, then every 2-3 days × 2-8 weeks
- Standard vancomycin 125 mg four times daily × 10 days (especially if metronidazole was used initially)
Adjunctive therapy: Bezlotoxumab 10 mg/kg IV once during antibiotic treatment reduces recurrence risk, particularly in high-risk patients (age >65, immunocompromised, severe CDI). Warning: Reserve for patients without congestive heart failure history due to FDA safety concerns. 1
Second or Subsequent Recurrence
Multiple options with equal standing:
- Fidaxomicin (standard or extended regimen)
- Tapered/pulsed vancomycin
- Vancomycin 125 mg four times daily × 10 days followed by rifaximin 400 mg three times daily × 20 days
- Fecal microbiota transplantation after at least 2 recurrences (3 total CDI episodes) 1
Important safety alert: FMT carries risk of pathogenic E. coli transmission (including fatalities) and potential SARS-CoV-2 transmission. Appropriate donor screening is mandatory. 1
Key Clinical Pitfalls
Do not stop IBD immunosuppression: In patients with inflammatory bowel disease and concurrent CDI, continue biologics, immunomodulators, and small molecules while treating CDI with antibiotics. Stopping immunosuppression worsens IBD outcomes without improving CDI outcomes. 3
Retesting considerations: In patients with persistent diarrhea after treatment, consider endoscopy at 48-72 hours to assess for ongoing IBD activity or cytomegalovirus coinfection rather than assuming treatment failure. 3
Avoid probiotics: Despite common practice, probiotics are not recommended for CDI prevention in any population. 3
Risk Stratification for Recurrence
High-risk patients who may benefit from bezlotoxumab include:
- Age >65 years
- Immunocompromised status
- Severe CDI on presentation
- History of prior CDI recurrence 1
The European guidelines emphasize that treatment strategy should prioritize recurrence risk over disease severity for individual patient management. 2